Article
Hematology
A. Birgitta Versluijs, Coco C. H. de Koning, Arjan C. Lankester, Stefan Nierkens, Wouter J. Kollen, Dorine Bresters, Caroline A. Lindemans, Jaap Jan Boelens, Marc Bierings
Summary: This study prospectively investigated the use of clofarabine-fludarabine-busulfan (CloFluBu) conditioning in allogeneic hematopoietic cell therapy, showing limited toxicity and encouraging event-free survival (EFS). The median age of all patients was approximately 9.7 years, with a 2-year EFS of 72.0% in acute lymphoid leukemia patients and 62.4% in acute myeloid leukemia patients.
Article
Hematology
Gheath Alatrash, Chantal Saberian, Roland Bassett, Peter F. Thall, Celina Ledesma, Yoshimi Lu, May Daher, Benigno C. Valdez, Jitesh Kawedia, Uday Popat, Rohtesh Mehta, Betul Oran, Yago Nieto, Amanda Olson, Paolo Anderlini, David Marin, Chitra Hosing, Amin M. Alousi, Elizabeth J. Shpall, Gabriela Rondon, Julianne Chen, Muzaffar Qazilbash, Richard E. Champlin, Partow Kebriaei
Summary: This study examined the long-term outcomes of adding vorinostat to the conditioning regimen for allogeneic hematopoietic stem cell transplantation. The results showed that there was no benefit in adding vorinostat to the standard regimen for high-risk leukemia patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Kimimori Kamijo, Yoshimitsu Shimomura, Akihito Shinohara, Shohei Mizuno, Minoru Kanaya, Yoshiaki Usui, Sung-Won Kim, Takahide Ara, Ishikazu Mizuno, Takuro Kuriyama, Hideyuki Nakazawa, Ken-ichi Matsuoka, Shigeru Kusumoto, Nobuo Maseki, Masaki Yamaguchi, Takashi Ashida, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo
Summary: By comparing the effects of Flu/Bu2 and Flu/Bu4 on patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation, the study found that Flu/Bu4 was associated with higher nonrelapse mortality and lower 5-year overall survival compared to Flu/Bu2.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
Summary: The study evaluated the safety and efficacy of PT-Cy combined with cyclosporine for GVHD prophylaxis in lymphoid malignancies after transplantation, showing the potential of this strategy in reducing the incidence of chronic GVHD.
FRONTIERS OF MEDICINE
(2021)
Article
Hematology
Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridi Levrat, Urs Schanz, Gayathri Nair, Marc Ansari, Patrick Simon, Jakob R. Passweg, Nathan Cantoni
Summary: Reversing the order of application of cyclophosphamide and busulfan in myeloablative conditioning for allo-HCT patients may lead to better outcomes. Short-term results show advantages of CyBu over BuCy in terms of liver toxicity, while long-term follow-up demonstrates lower non-relapse mortality and higher survival with CyBu compared to BuCy.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Roswitha Luftinger, Natalia Zubarovskaya, Jacques-Emmanuel Galimard, Annamaria Cseh, Elisabeth Salzer, Franco Locatelli, Mattia Algeri, Akif Yesilipek, Josu de la Fuente, Antonella Isgro, Amal Alseraihy, Emanuele Angelucci, Frans J. Smiers, Giorgia La La Nasa, Marco Zecca, Tunc Fisgin, Emel Unal, Katharina Kleinschmidt, Christina Peters, Arjan Lankester, Selim Corbacioglu
Summary: Significant advances in supportive care have improved the life expectancy of patients with transfusion-dependent thalassemia major (TDT), but iron overload remains a barrier to long-term survival. This retrospective analysis compared the outcomes of TDT patients undergoing hematopoietic stem cell transplantation (HSCT) with different conditioning regimens, and found that both busulfan-fludarabine-based and treosulfan-fludarabine-based conditioning resulted in high cure rates. The main causes of death were infections, graft-versus-host disease, and rejection.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Ally Fraser, Paul Castillo, Erika Cascio, Giselle Moore-Higgs, Nosha Farhadfar, John Fort, William Slayton, Jatinder Lamba, Biljana Horn
Summary: This study aimed to determine the minimum effective dose (MED) of thiotepa in combination with reduced-dose busulfan, fludarabine or cyclophosphamide, and rATG to achieve engraftment in >90% of HSCT recipients with non-malignant disorders. The results showed that all six patients achieved engraftment prior to Day +42 and none of them experienced disease recurrence.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Benigno C. Valdez, Bin Yuan, David Murray, Jeremy Leon Ramdial, Yago Nieto, Uday Popat, Xiaowen Tang, Borje S. Andersson
Summary: Combinations of nucleoside analog(s) and DNA alkylating agent(s) are used for cancer treatment. This study found that adding the HDAC inhibitor SAHA and the PARP inhibitor olaparib to the established drug combination can enhance the cytotoxicity of AML cells.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Matthew P. Connor, Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar I. Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, Alison Carulli, Christopher Catania, Jacqueline Smith, Lauren Hollander, Alexis M. Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle Frey
Summary: Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. The use of a myeloablative conditioning regimen combining clofarabine with busulfan has shown antileukemic activity with acceptable toxicity in patients under 70 years old. This study evaluates the clinical outcomes of patients with active myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT) with the clofarabine-busulfan regimen, and concludes that it is an effective transplantation strategy, particularly for patients with advanced myelodysplastic syndrome (MDS).
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Pharmacology & Pharmacy
Ai-Hoc Nguyen, Mohitosh Biswas, Apichaya Puangpetch, Santirhat Prommas, Samart Pakakasama, Usanarat Anurathapan, Jiratha Rachanakul, Rattanaporn Sukprasong, Nutthan Nuntharadtanaphong, Nutcha Jongjitsook, Suradej Hongeng, Chonlaphat Sukasem
Summary: This study found a significant association between the polymorphism of GSTA1 and variations in the pharmacokinetic properties of busulfan treatment in pediatric Asian patients. Patients carrying the GSTA1*B variant showed a significant impact on the PK of busulfan, with a notable augmentation in AUC.
Article
Biophysics
Anne Banet, Ali Bazarbachi, Myriam Labopin, Nicolas Stocker, Remy Dulery, Florent Malard, Zoe Van de Wyngaert, Alexis Genthon, Mara Memoli, Ollivier Legrand, Agnes Bonnin, Tounes Ledraa, Ramdane Belhocine, Simona Sestili, Jean El-Cheikh, Mohamad Mohty, Eolia Brissot
Summary: Total body irradiation (TBI)-based conditioning regimens are commonly used in acute lymphoblastic leukemia (ALL) patients, but studies have shown comparable outcomes with thiotepa-based conditioning regimen. In this retrospective study, we evaluated the outcome of adult ALL patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with a thiotepa-busulfan-fludarabine (TBF) myeloablative conditioning regimen. The results showed promising overall survival and acceptable toxicity in these patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji
Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Daniel P. Noij, Martin van den Bent, Jeanette K. Doorduijn, Nick Wlazlo
Summary: We report a case of a 19-year-old patient who experienced two episodes of donor-derived PCNSL after undergoing allogeneic stem cell transplantation in childhood. Despite failed induction chemotherapy, successful consolidation therapy was achieved through a second allogeneic stem cell transplantation after conditioning with thiotepa, busulfan, and fludarabine.
ACTA HAEMATOLOGICA
(2023)
Article
Biophysics
Borje S. Andersson, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Roland Bassett, Julianne Chen, Sairah Ahmed, Amin Alousi, Qaiser Bashir, Stefan Ciurea, Alison Gulbis, Rita Cool, Jitesh Kawedia, Chitra Hosing, Partow Kebriaei, Steve Kornblau, Alan Myers, Betul Oran, Katayoun Rezvani, Nina Shah, Elizabeth Shpall, Simrit Parmar, Uday R. Popat, Yago Nieto, Richard E. Champlin
Summary: Pretransplant conditioning with Fludarabine-Busulfan is safe, but clofarabine has improved antileukemic activity. This study aimed to evaluate the efficacy of Flu+Clo-Bu (FCB) compared to Flu-Bu in AML/MDS patients undergoing allogeneic transplantation. The results showed that FCB had a lower relapse incidence but higher non-relapse mortality compared to Flu-Bu. FCB showed improved disease control in NCR patients with low HCT-CI scores. Confirmatory trials are needed to further assess the effectiveness of FCB.
BONE MARROW TRANSPLANTATION
(2022)
Article
Pharmacology & Pharmacy
Yuan-Yuan Shi, Zeng-Yan Liu, Gui-Xin Zhang, Yi He, Ming-Zhe Han, Si-Zhou Feng, Rong-Li Zhang, Er-Lie Jiang
Summary: This study explores the safety and effectiveness of a cladribine-based conditioning regimen for autologous hematopoietic stem cell transplantation in patients with acute myeloid leukemia. The results indicate that this regimen is a successful and safe approach for AML treatment.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biophysics
Piyanuch Kongtim, Simrit Parmar, Denai R. Milton, Jorge Miguel Ramos Perez, Gabriela Rondon, Julianne Chen, Abhishek R. Chilkulwar, Gheath Al-Atrash, Amin Alousi, Borje S. Andersson, Jin S. Im, Chitra M. Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Betul Oran, Uday Popat, Richard Champlin, Stefan O. Ciurea
BONE MARROW TRANSPLANTATION
(2019)
Article
Biophysics
Gheath Alatrash, Kelly M. Kidwell, Peter F. Thall, Antonio Di Stasi, Julianne Chen, Madhushree Zope, Alyssa K. Crain, Richard E. Champlin, Uday Popat, Elizabeth J. Shpall, Roy B. Jones, Borje S. Andersson
BONE MARROW TRANSPLANTATION
(2019)
Article
Oncology
Patrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, Christopher S. Hourigan, Karolyn A. Oetjen, Jorge E. Cortes, Farhad Ravandi, Elias J. Jabbour, Zainab Al-Hamal, Marina Konopleva, Jing Ning, Lianchun Xiao, Juliana Hidalgo Lopez, Steve M. Kornblau, Michael Andreeff, Wilmer Flores, Carlos Bueso-Ramos, Jorge Blando, Pallavi Galera, Katherine R. Calvo, Gheath Al-Atrash, James P. Allison, Hagop M. Kantarjian, Padmanee Sharma, Naval G. Daver
Article
Oncology
Gheath Alatrash, Na Qiao, Mao Zhang, Madhushree Zope, Alexander A. Perakis, Pariya Sukhumalchandra, Anne Philips, Haven R. Garber, Celine Kerros, Lisa S. St John, Maria R. Khouri, Hiep Khong, Karen Clise-Dwyer, Leonard P. Miller, Steve Wolpe, Willem W. Overwijk, Jeffrey J. Molldrem, Qing Ma, Elizabeth J. Shpall, Elizabeth A. Mittendorf
CLINICAL CANCER RESEARCH
(2019)
Article
Hematology
Kamal Chamoun, Denai R. Milton, Celina Ledesma, Ken H. Young, Elias J. Jabbour, Gheath Alatrash, Paolo Anderlini, Qaiser Bashir, Stefan O. Ciurea, David Marin, Jeffrey J. Molldrem, Amanda L. Olson, Betul Oran, Uday R. Popat, Gabriela Rondon, Richard E. Champlin, Alison M. Gulbis, Issa F. Khouri
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2019)
Review
Oncology
Haven R. Garber, Jennifer K. Litton
CURRENT OPINION IN ONCOLOGY
(2019)
Article
Oncology
Peter S. N. van Rossum, Wei Deng, David M. Routman, Amy Y. Liu, Cai Xu, Yutaka Shiraishi, Max Peters, Kenneth W. Merrell, Christopher L. Hallemeier, Radhe Mohan, Steven H. Lin
PRACTICAL RADIATION ONCOLOGY
(2020)
Article
Hematology
Samer A. Srour, Rima M. Saliba, Maria C. B. Bittencourt, Jorge M. R. Perez, Piyanuch Kongtim, Amin Alousi, Gheath Al-Atrash, Amanda Olson, Oran Betul, Rohtesh Mehta, Uday Popat, Chitra Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Lucia Masarova, Nicholas Short, Elias Jabbour, Naval Daver, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Richard E. Champlin, Stefan O. Ciurea
AMERICAN JOURNAL OF HEMATOLOGY
(2019)
Article
Oncology
G. Travis Clifton, Diane Hale, Timothy J. Vreeland, Annelies T. Hickerson, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne V. Philips, Jason J. Lukas, Jarrod P. Holmes, George E. Peoples, Elizabeth A. Mittendorf
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Hong He, Yukio Kondo, Ken Ishiyama, Gheath Alatrash, Sijie Lu, Kathryn Cox, Na Qiao, Karen Clise-Dwyer, Lisa St John, Pariya Sukhumalchandra, Qing Ma, Jeffrey J. Molldrem
Article
Oncology
Cai Xu, Jian-Yue Jin, Ming Zhang, Amy Liu, Jun Wang, Radhe Mohan, Fengming (Spring) Kong, Steven H. Lin
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero, Jin S. Im
Summary: The purpose of this study is to find immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy and/or hypomethylating agent treatment. Peripheral blood samples from 55 MDS patients were analyzed for immune subsets, T-cell receptor repertoire, gene mutations, and immune-related gene expression profiling. The results showed that clinical responders to immunotherapy exhibited expansion of central memory CD8+ T cells, diverse TCR repertoire, higher mutation burden, and favorable changes in immune landscape.
CLINICAL CANCER RESEARCH
(2023)
Article
Hematology
Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.
Article
Engineering, Biomedical
Cong Zhu, Steven H. Lin, Xiaoqian Jiang, Yang Xiang, Zayne Belal, Goo Jun, Radhe Mohan
PHYSICS IN MEDICINE AND BIOLOGY
(2020)